CoChat
Sign Up
Cited by 583Lipoproteins and Cardiovascular HealthCholesterol and Lipid MetabolismDiabetes, Cardiovascular Risks, and Lipoproteins

The apoB/apoA‐I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid‐lowering therapy – a review of the evidence

Open access
WALLDIUS, G., JUNGNER, I.·2006·Journal of Internal Medicine
DOI 10.1111/j.1365-2796.2006.01643.x
Open this paper in CoChat — free accountOpen PDF

Abstract

Abstract.: During the last several years interest has focused on the importance of the lipid‐transporting apolipoproteins – apoB transports all potentially atherogenic very low‐density lipoprotein (VLDL), intermediate‐density lipoprotein (IDL) and LDL particles, and apoA‐I transports and acts as the major antiatherogenic protein in the HDL particles. The evidence for the apoB/apoA‐I ratio being a strong, new risk factor for cardiovascular (CV) disease and a target for lipid‐lowering therapy is reviewed. Results from clinical prospective studies and lipid‐lowering trials in healthy subjects and in patients with different clinical manifestations of atherosclerosis are reported. Risk of nonfatal and fatal myocardial infarction and stroke, and manifestations of atherosclerosis documented by angiographic, ultrasound and other techniques has been related to conventional lipids and apolipoproteins (apo). The cholesterol balance determined as the apoB/apoA‐I ratio has repeatedly been shown to be a better marker than lipids, lipoproteins and lipid ratios. The results indicate that the apoB/apoA‐I ratio is a simple, accurate and new risk factor for CV disease – the lower the apoB/apoA‐I ratio, the lower is the risk. Guidelines should be developed in order to recognize the important clinical risk information embedded in the apoB/apoA‐I ratio.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2796.2006.01643.x

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • ApoB-48 is a specific measure of chylomicrons and their remnants.

    “In addition, apoB-48 is a specific measure of chylomicrons and their remnants (2, 3) .”

    From Automated multiplex LC-MS/MS assay for quantifying serum apolipoproteins A-I, B, C-I, C-II, C-III, and E with qualitative apolipoprotein E phenotyping (2016) · cites this paper as [2]

    The Apolipoprotein B section says apoB-48 is synthesized in the gut and discusses its low plasma abundance, but does not say it specifically measures chylomicrons or their remnants. Searches for “chylomicrons and their remnants,” “apoB-48 chylomicron remnant specific measure,” and “chylomicron” found no passage establishing that point. (LLM, conf=0.72)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 124

  1. Adult Treatment Panel III. Executive summary of the third report of the National Cholesterol Education Program (NECP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. J Am Med Assoc 2001; 285: 2486-97.
  2. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358: 2026-33.
  3. Ó 2006 Blackwell Publishing Ltd Journal of Internal Medicine 259: 493-519
  4. Walldius G, Aastveit AH, Jungner I. Stroke mortality and the apoB/apoA-I ratio: results of the AMORIS prospective study. J Intern Med 2006; 259: 259-66.
  5. Marcovina S, Packard CJ. Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels. J Intern Med 2006; 259: 437-46.
  6. Elovson J, Chatterton JE, Bell GT et al. Plasma very low density lipoproteins contain a single molecule of apolipo- protein B. J Lipid Res 1988; 29: 1461-73.
  7. Sniderman AD, Furberg CD, Keech A et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin therapy treatment. Lancet 2003; 361: 777-80.
  8. Sniderman AD, Barter PJ, Ballantyne CM et al. Report of the thirty person/ten country panel. ApoB versus cholesterol to estimate cardiovascular risk and to guide therapy. J Intern Med 2006; 259: 247-58.
  9. Rader DJ, Hoeg JM, Brewer HB Jr. Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. Ann Intern Med 1994; 120: 1012- 25.
  10. Lamarche B, Moorjani S, Lupien PJ et al. Apolipoprotein A-1 and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Que ´bec Cardiovascular Study. Circulation 1996; 94: 273-8.
  11. Talmud PJ, Hawe E, Miller GJ, Humphries SE. Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men. Arterioscler Thromb Vasc Biol 2002; 22: 1918-23.
  12. Sharrett AR, Ballantyne CM, Coady SA et al. Coronary heart disease prediction from lipoprotein cholesterol levels, tri- glycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001; 104: 1108- 13.
  13. Valero R, Lorec A-M, Paganelli F et al. Fasting apoprotein B-48 and coronary artery disease in a population without frank fasting hypertriglyceridemia. Metabolism 2005; 54: 1442-7.
  14. Sniderman AD, St-Pierre A, Cantin B, Dagenais GR, Depre ´s J-P, Lamarche B. Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. Am J Cardiol 2003; 91: 1173-7.
  15. Sniderman AD. Apolipoprotein B versus non-high-density lipoprotein cholesterol. And the winner is…. Circulation 2005; 112: 3336-67 (Editorial).
  16. Kim BJ, Hwang ST, Sung KC et al. Comparison of the rela- tionships between serum apolipoprotein B and serum lipid distributions. Clin Chem 2005; 51: 2257-63.
  17. Walldius G, Jungner I, Aastveit AH, Holme I, Furberg CD, Sniderman AD. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clin Chem Lab Med 2004; 42: 1355- 63.
  18. Sniderman AD, Jungner I, Holme I, Aastveit A, Walldius G. Errors that result from using the TC/HDL C ratio rather than the apoB/apoA-I ratio to identify the lipoprotein- related risk of vascular disease. J Intern Med 2006; 259: 455-61.
  19. Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 2005; 112: 3375-83.
  20. Liu J, Sempos C, Donahue RP, Dorn J, Trevisan M, Grundy SM. Joint distribution of non-HDL and LDL cholesterol and coronary heart disease risk prediction among individuals with and without diabetes. Diabetes Care 2005; 28: 1916- 21.
  21. Jiang R, Schulze MB, Li T et al. Non-HDL cholesterol and apolipoprotein b predict cardiovascular disease events among men with type 2 diabetes. Diabetes Care 2004; 27: 1991-7.
  22. Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non- HDL cholesterol, apolipoproteins A-I and B-100, standard lipid measures, lipid ratios, and CRP as risk factors for car- diovascular disease in women. J Am Med Assoc 2005; 294: 326-33.
  23. Schlitt A, Blankenberg S, Bickel C et al. Prognostic value of lipoproteins and their relation to inflammatory markers among patients with coronary artery disease. Int J Cardiol 2005; 102: 477-85.
  24. Shah PK, Kaul S, Nilsson J, Cercek B. Exploiting the vascular protective effects of high-density lipoprotein and its apo- lipoproteins. An idea whose time for testing is coming: Part I. Circulation 2001; 104: 2376-83.
  25. Barter PJ, Rye K-A. The rationale for using apoA-I as a clinical marker of cardiovascular risk. J Intern Med 2006; 259: 447-54.
  26. Nissen SE, Tsunoda T, Tuzcu EM et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes. A randomized controlled trial. J Am Med Assoc 2003; 290: 2292-300.
  27. Skinner JS, Farrer M, Albers CJ, Neil HA, Adams PC. High apolipoprotein AI concentrations are associated with lower mortality and myocardial infarction five years after coron- ary artery bypass graft surgery. Heart 1999; 81: 488-94.
  28. Sharp DS, Burchfield CM, Rodriguez BL, Sharrett AR, Sorlie PD, Marcovina SM. Apolipoprotein A-I predicts coronary heart disease only at low concentrations of high-density lipoprotein cholesterol: an epidemiological study of Japan- ese-Americans. Int J Clin Lab Res 2000; 30: 39-48.
  29. Francis M, Frohlich JJ. Coronary artery disease in patients at low risk -apolipoprotein AI as an independent risk factor. Atherosclerosis 2001; 155: 165-70.
  30. Luc G, Bard J-M, Ferrie `res J et al. Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Arterioscler Thromb Vasc Biol 2002; 22: 1155-61.
  31. Asztalos BF, Horvath KV, McNamara JR, Roheim PS, Rubinstein JJ, Schaefer EJ. Comparing the effects of five dif- ferent statins on the HDL subpopulation profiles of coronary heart disease patients. Atherosclerosis 2002; 164: 361-9.
  32. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
  33. Ballantyne CM, Hoogeveen RC. Role of lipid and lipoprotein profiles on risk assessment and therapy. Am Heart J 2003; 146: 227-33.
  34. Marcovina SM, Albers JJ, Henderson LO, Hannon WH. International Federation of Clinical Chemistry standardiza- tion project for measurements of apolipoproteins A-I and B: III. Comparability of apolipoprotein A-I values by use of International Reference Material. Clin Chem 1993; 39: 773- 81.
  35. Marcovina SM, Albers JJ, Kennedy H, Mei JV, Henderson LO, Hannon WH. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B: IV. Comparability of apolipoprotein B values by use of International Reference Material. Clin Chem 1994; 40: 586-92.
  36. van Lennep JE, Westerveld HT, van Lennep HWO, Zwin- derman AH, Erkelens DW, van der Wall EE. Apolipoprotein concentrations during treatment and recurrent coronary artery disease events. Arterioscler Thromb Vasc Biol 2000; 20: 2408-13.
  37. Walldius G, Jungner I, Kolar W, Holme I, Steiner E. High cholesterol and triglyceride values in Swedish males and females: increased risk of fatal myocardial infarction: First report from the AMORIS (Apolipoprotein related MOrtality RISk) Study. Blood Press 1992; 1(Suppl. 4): 35-42.
  38. Jungner I, Walldius G, Holme I, Kolar W, Steiner E. Apo- lipoprotein B and A-1 in relation to serum cholesterol and triglycerides in 43 000 Swedish males and females. Int J Clin Lab Res 1992; 21: 247-55.
  39. Jungner I, Marcovina SM, Walldius G, Holme I, Kolar W, Steiner E. Swedish males and females, standardized accord- ing to the World Health Organization-International Feder- ation of Clinical Chemistry First International Reference Materials. Clin Chem 147; 576: 1641-9.
  40. Walldius G, Aastveit A, Jungner I. Hypercholesterolemia and hypertriglyceridemia -greatest cardiac risk in subjects with high apoB/apoA-I levels. Int Congr Ser 2004; 1262: 203-6.
  41. Jungner I, Sniderman AD, Furberg C, Aastveit AH, Holme I, Walldius G. Does low-density lipoprotein size add to ather- ogenic particle number in predicting the risk of fatal myo- cardial infarction? Am J Cardiol 2006; 97: 943-6.
  42. Di Napoli P, Taccardi AA, Oliver M, De Caterina R. Statins and stroke: evidence for cholesterol-independent effects. Eur Heart J 2002; 23: 1908-21.
  43. Weverling-Rijnsburger AWF, Jonkers IJAM, van Exel E, Gussekloo J, Westendorp RGJ. High-density vs low-density lipoprotein cholesterol as the risk factor for coronary artery disease and stroke in old age. Arch Intern Med 2003; 163: 1549-54.
  44. Chien K-L, Sung F-C, Hsu H-C, Su T-C, Lin R-S, Lee Y-T. Apolipoprotein A-I and B and stroke events in a community- based cohort in Taiwan. Report of the Chin-Shan Commu- nity Cardiovascular Study. Stroke 2002; 33: 39-44.
  45. Tirschwell DL, Smith NL, Heckbert SR, Lemaitre RN, Longstreth WT, Psaty BM. Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups. Neurology 2004; 63: 1868-75.
  46. Witt BJ, Brown RD Jr, Jacobsen SJ, Weston SA, Yawn BP, Roger VL. A community-based study of stroke incidence after myocardial infarction. Ann Intern Med 2005; 143: 785-92.
  47. Steyn K, Sliwa K, Hawken S et al. Risk factors associated with myocardial infarction in Africa: the INTERHEART Africa study. Circulation 2005; 112: 3554-61.
  48. Dunder K, Lind L, Zethelius B, Berglund L, Lithell H. Eval- uation of a scoring scheme, including proinsulin and the apolipoprotein B/apolipo-protein AI ratio, for the risk of acute coronary events in middle-aged men: Uppsala Longi- tudinal Study of Adult Men (ULSAM). Am Heart J 2004; 148: 596-601.
  49. Stro ¨m-Mo ¨ller C, Zethelius B, Sundstro ¨m J, Lind L. Impact of follow-up time and re-measurement of the electrocardio- gram and conventional cardiovascular risk factors on their predictive value for myocardial infarction. J Intern Med 2006 (in press).
  50. Ingelsson E, A ¨rnlo ¨v J, Sundstro ¨m J, Zethelius B, Vessby B, Lind L. Novel metabolic risk factors for heart failure. J Am Coll Cardiol 2005; 46: 2054-60.
  51. Boekholdt SM, van der Steeg WA, Stein EA et al. The ratio of apolipoproteins B to A-I and the risk of future coronary artery disease in apparently healthy men and women; the EPIC-Norfolk prospective population study. Ann Intern Med 2006 (in press).
  52. Meisinger C, Loewel H, Mraz W, Koenig W. Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study. Eur Heart J 2005; 26: 271-8.
  53. Shai I, Rimm EB, Hankinson SE et al. Multivariate assess- ment of lipid parameters as predictors of coronary heart disease among postmenopausal women. Potential impli- cations for clinical guidelines. Circulation 2004; 110: 2824-30.
  54. Moss AJ, Goldstein RE, Marder VJ et al. Thrombogenic fac- tors and recurrent coronary events. Circulation 1999; 99: 2517-22.
  55. Corsetti JP, Zareba W, Moss AJ, Sparks CE. Apolipoprotein B determines risk for recurrent coronary events in postin- farction patients with metabolic syndrome. Atherosclerosis 2004; 177: 367-73.
  56. Sattar N, Williams K, Sniderman AD, D'Agostino R Jr, Haffner SM. Comparison of the associations of apolipopro- tein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the meta- bolic syndrome in the Insulin Resistance Atherosclerosis Study. Circulation 2004; 110: 2687-93.
  57. Cremer P, Nagel D, Mann H et al. Ten-year follow-up results from the Goettingen Risk, Incidence and Prevalence Study (GRIPS): I. Risk factors for myocardial infarction in a cohort of 5790 men. Atherosclerosis 1997; 129: 221- 30.
  58. Sweetnam PM, Bolton CH, Downs LG et al. Apolipoproteins A-I, A-II and B, lipoprotein(a) and the risk of ischaemic heart disease: the Caerphilly Study. Eur J Clin Invest 2000; 30: 947-56.
  59. Stewart MW, Humphriss DB, Mitcheson J, Webster J, Walker M, Laker MF. Lipoprotein composition and serum apolipo- proteins in normoglycaemic first-degree relatives of non- insulin dependent diabetic patients. Atherosclerosis 1998; 139: 115-21.
  60. Sung KC, Hwang ST. Association between insulin resistance and apolipoprotein B in normoglycemic Koreans. Athero- sclerosis 2005; 189: 161-9.
  61. Kim H-K, Chang S-A, Choi E-K et al. Association between plasma lipids, and apolipoproteins and coronary artery dis- ease: a cross-sectional study in a low-risk Korean popula- tion. Int J Cardiol 2005; 101: 435-40.
  62. Snehalatha C, Ramachandran A, Sivasankari S et al. Is in- creased apolipoprotein B-A major factor enhancing the risk of coronary artery disease in type 2 diabetes? J Assoc Phy- sicians India (JAPI) 2002; 50: 1036-8.
  63. Al-Bahrani AI, Bakhiet CS, Bayoumi RA, Al-Yakyaee SA. A potential role of apolipoprotein B in the risk stratification of diabetic patients with dyslipidaemia. Diabetes Res Clin Pract 2005; 69: 44-51.
  64. Smith J, Amri MA, Sniderman AD. What do we (not) know about apoB, type 2 diabetes and obesity. Diabetes Res Clin Pract 2005; 69: 99-101 (Commentary).
  65. Sniderman AD, Scantlebury T, Cianflone K. Hypertriglycer- idemic hyperapoB: the unappreciated atherogenic dyslipo- proteinemia in type 2 diabetes mellitus. Ann Intern Med 2001; 135: 447-59.
  66. Solymoss BC, Bourassa MG, Campeau L et al. Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severity. Am J Cardiol 2004; 93: 159-64.
  67. Lind L, Vessby B, Sundstro ¨m J. The apolipoprotein B/AI ratio and the metabolic syndrome independently predict risk for myocardial infarction in middle-aged men. Arterioscler Thromb Vasc Biol 2006; 26: 406-10.
  68. Tanko ´LB, Bagger YZ, Qin G, Alexandersen P, Larsen PJ, Christiansen C. Enlarged waist combined with elevated tri- glycerides is a strong predictor of accelerated atherogenesis and related cardiovascular mortality in postmenopausal women. Circulation 2005; 111: 1883-90.
  69. Maffeis C, Pietrobelli A, Grezzani A, Provera S, Tato `L. Waist circumference and cardiovascular risk factors in prepubertal children. Obes Res 2001; 9: 179-87.
  70. Gardner CD, Tribble DL, Young DR, Ahn D, Fortmann SP. Associations of HDL, HDL 2 , and HDL 3 cholesterol and apo- lipoprotein A-I and B with lifestyle factors in healthy men and women: The Stanford Five City Project. Prev Med 2000; 30: 346-56.
  71. Okosun IS, Prewitt TE, Liao Y, Cooper RS. Association of waist circumference with ApoB to ApoA-I ratio in black and white Americans. Int J Obes Relat Metab Disord 1999; 23: 498-504.
  72. Kobayashi S, Maesato K, Moriya H, Ohtake T, Ikeda T. Insulin resistance in patients with chronic kidney disease. Am J Kidney Dis 2005; 45: 275-80.
  73. Batista MC, Welty FK, Diffenderfer MR et al. Apolipoprotein A-I, B-100, and B-48 metabolism in subjects with chronic kidney disease, obesity, and the metabolic syndrome. Meta- bolism 2004; 53: 1255-61.
  74. Horimoto M, Hasegawa A, Ozaki T, Takenaka T, Igarashi K, Inoue H. Independent predictors of the severity of angio- graphic coronary atherosclerosis: the lack of association between impaired glucose tolerance and stenosis severity. Atherosclerosis 2005; 182: 113-9.
  75. Garfagnini A, Devoto G, Rosselli P, Boggiano P, Venturini M. Relationship between HDL C and apolipoprotein A-I and the severity of coronary artery disease. Eur Heart J 1995; 16: 465-70.
  76. Rahmani M, Raiszadeh F, Allahverdian S, Kiaii S, Navab M, Azizi F. Coronary artery disease is associated with the ratio of apolipoprotein A-I/B and serum concentration of apolipoprotein B, but not with paraoxonase enzyme activity in Iranian subjects. Atherosclerosis 2002; 162: 381-9.
  77. Westerveld HT, Roeters van Lennep JE, Roeters van Lennep HWO et al. Apolipoprotein B and coronary artery disease in women: a cross-sectional study in women undergoing their first coronary angiography. Arterioscler Thromb Vasc Biol 1998; 18: 1101-7.
  78. Haidari M, Moghadam M, Chinicar M, Ahmadieh A, Doosti M. Apolipoprotein B as the best predictor of coronary artery disease in Iranian normolipidemic patients. Clin Biochem 2001; 34: 149-55.
  79. Simon A, Chironi G, Gariepy J, Del Pino M, Levenson J. Differences between markers of atherogenic lipoproteins in predicting high cardiovascular risk and subclinical athero- sclerosis in asymptomatic men. Atherosclerosis 2005; 179: 339-44.
  80. Wallenfeldt K, Bokemark L, Wikstrand J, Hulthe J, Fagerberg B. Apolipoprotein B/apolipoprotein A-I in relation to the metabolic syndrome and change in carotid artery intima- media thickness during 3 years in middle-aged men. Stroke 2004; 35: 2248-52.
  81. Jadhav UM, Kadam NN. Apolipoproteins: correlation with carotid intima media thickness and coronary artery disease. J Assoc Physicians India 2004; 52: 370-5.
  82. Snehalatha C, Vijay V, Suresh Mohan R et al. Lack of association of insulin resistance and carotid intimal medial thickness in non-diabetic Asian Indian subjects. Diabetes Metab Res Rev 2001; 17: 444-7.
  83. Schott LL, Wildman RP, Brockwell S, Simkin-Silverman LR, Kuller LH, Sutton-Tyrrell K. Segment-specific effects of car- diovascular risk factors on carotid artery intima-medial thickness in women at midlife. Arterioscler Thromb Vasc Biol 2004; 24: 1951-6.
  84. Sebestjen M, Zegura B, Videcnik V, Keber I. Determinants of endothelial dysfunction and carotid intima-media thickness in combined hyperlipidemia. Coron Artery Dis 2005; 16: 175-80.
  85. Elbaz M, Carrie ´D, Baudeux JL et al. High frequency of endothelial vasomotor dysfunction after acute coronary syndromes in non-culprit and angiographically normal coronary arteries: a reversible phenomenon. Atherosclerosis 2005; 181: 311-9. 100
  86. Steer P, Hulthe J, Millga ˚rd J et al. Endothelial vasodilatory function is predicted by circulating apolipoprotein B and HDL in healthy humans. Lipids 2002; 37: 1135-40. 101
  87. Kurvinen E, Aasvee K, Zordania R, Jauhiainen M, Sundvall J. Serum lipid and apolipoprotein profiles in newborns and six-year-old children: The Tallin Young Family Study. Scand J Clin Lab Invest 2005; 65: 541-50. 104
  88. Keavney B, Palmer A, Parish S et al. Lipid-related genes and myocardial infarction in 4685 cases and 3460 controls: discrepancies between genotype, blood lipid concentrations, and coronary disease risk. Int J Epidemiol 2004; 33: 1002-13. 105
  89. Makedou A, Kourti M, Makedou K, Lazaridou S, Varlamis G. Lipid profile of children with a family history of coronary heart disease or hyperlipidemia: 9-year experience of an outpatient clinic for the prevention of cardiovascular risk. Angiology 2005; 56: 391-5. 106
  90. Freedman DS, Srinivasan SR, Shear CL, Franklin SA, Web- ber LS, Berenson GS. The relation of apolipoproteins A-I and B in children to parental myocardial infarction. N Engl J Med 1986; 315: 721-6. 107
  91. Srinivasan SR, Berenson GS. Apolipoprotein B and A-I as predictors of risk of coronary artery disease. Lancet 2001; 358: 2012-3. 108
  92. Srinivasan SR, Berenson GS. Serum apolipoproteins A-I and B as markers of coronary artery disease risk in early life: the Bogalusa Heart Study. Clin Chem 1995; 41: 159-64. 109
  93. Keulen ETP, Kruijshoop M, Schaper NC, Hoeks APG, de Bruin TWA. Increased intima-media thickness in familial combined hyperlipidemia associated with apolipoprotein B. Arterioscler Thromb Vasc Biol 2002; 22: 283-8. 111
  94. Zambon A, Brown BG, Deeb SS, Brunzell JD. Genetics of apolipoprotein B and apolipoprotein AI and premature cor- onary artery disease. J Intern Med 2006; 259: 473-80. 112
  95. Charlton-Menys V, Durrington P. Apolipoproteins A-I and B as therapeutic targets. J Intern Med 2006; 259: 462-72. 113
  96. Scharnagl H, Nauck M, Wieland H, Ma ¨rz W. The Friedewald formula underestimates LDL cholesterol at low concentra- tions. Clin Chem Lab Med 2001; 39: 426-31. 115
  97. Otvos JD. Why cholesterol measurements may be misleading about lipoprotein levels and cardiovascular disease risk - clinical implications of lipoprotein quantification using NMR spectroscopy. J Lab Med 2002; 26: 544-50. 116
  98. Sniderman AD, Blank D, Zakarian R, Bergeron J, Frohlich J. Triglycerides and small dense LDL: the twin Achilles heels of the Friedewald formula. Clin Biochem 2003; 36: 499-504. 117
  99. Steinmetz J, Tarallo P, Fournier B, Caces E, Siest G. Refer- ence limits of apolipoprotein A-I and apolipoprotein B using an IFCC standard immunonephelometric method. Eur J Clin Chem Clin Biochem 1995; 33: 337-42. 119
  100. Steinmetz J, Caces E, Couderc R, Beucler I, Legrand A, Henney J. Reference values of apolipoproteins AI and B. Contribution of International standardization. Ann Biol Clin 1997; 55: 451-4. 120
  101. Denke MA. Weighing in Before the Fight. Low-density lip- optotein cholesterol and non-high-density lipoprotein cho- lesterol versus apolipoprotein B as the best predictor for coronary heart disease and the best measure of therapy. Circulation 2005; 112: 3368-70 (Editorial). 121
  102. Bachorik PS, Lovejoy KL, Carroll MD, Johnson CL. Apo- lipoprotein B and AI distributions in the United States, 1988-1991: results of the National Health and Nutrition Examination Survey III (NHANES III). Clin Chem 1997; 43: 2364-78. 122
  103. Genest J, Frohlich J, Fodor G, McPherson R for the Working Group on Hypercholesterolemia and other Dyslipidemias. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. Can Med Assoc J 2003; 169: 921-4. 123
  104. Contois JH, McNamara JR, Lammi-Keefe CJ, Wilson PWF, Massow T, Schaefer EJ. Reference intervals for plasma apo- lipoprotein B determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study. Clin Chem 1996; 42: 515-23. 124
  105. Contois JH, McNamara JR, Lammi-Keefe CJ, Wilson PWF, Massow T, Schaefer EJ. Reference intervals for plasma apo- lipoprotein A-I determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study. Clin Chem 1996; 42: 507-14. 125
  106. Connelly PW, Poapst M, Davignon J et al. Reference values of plasma apolipoproteins A-I and B, and association with nonlipid risk factors in the populations of two Canadian provinces: Quebec and Saskatchewan. Can J Cardiol 1999; 15: 409-18. 126
  107. Leino A, Impivaara O, Kaitsaari M, Ja ¨visalo J. Serum con- centrations of apolipoprotein A-I, apolipoprotein B, and apolipoprotein (a) in a Finnish sample. Clin Chem 1995; 41: 1633-6. 127
  108. Graziani MS, Zanolla L, Righetti G, Marchetti C, Mocarelli P, Marcovina SM. Plasma apolipoprotein A-O and B in survi- vors of myocardial infarction and in a control group. Clin Chem 1998; 44: 134-40. 128
  109. Contois JH, Wu AH, Li Z et al. Distribution of serum apo- lipoproteins A-I and B and lipoprotein(a) in European el- derly. The SENECA study. Clin Chim Acta 2000; 295: 1-12. 129
  110. Gardner CD, Tribble DL, Young DR, Ahn D, Fortmann SP. Population frequency distributions of HDL, HDL 2 , and HDL 3 cholesterol and apolipoprotein A-I and B in healthy men and women and associations with age, gender, hormonal status, and sex hormone use: The Stanford Five City Project. Prev Med 2000; 30: 335-45. 130
  111. Sakurabayashi I, Saito Y, Kita T, Matsuzawa Y, Goto Y. Reference intervals for serum apolipoproteins A-I, A-II, B, C- II, C-III. and E in healthy Japanese determined with a commercial immunoturbidimetric assay and effects of sex, age, smoking, drinking and Lp(a) level. Clin Chim Acta 2001; 312: 87-95. 131
  112. Durrington PN, Tuomilehto J, Hamann A, Kallend D, Smith K. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. Diabetes Res Clin Pract 2004; 64: 137-51. 133
  113. Jukema JW, Liem AH, Dunselman PH, van der Sloot JA, Lok DJ, Zwinderman AH. LDL C/HDL C ratio in subjects with cardiovascular disease and a low HDL C: results of the RA- DAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study. Curr Med Res Opin 2005; 21: 1865-74. 134
  114. Wolffenbuttel BHR, Franken AAM, Vincent HH on behalf of the Dutch CORALL Study Group. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in pa- tients with type 2 diabetes -CORALL study. J Intern Med 2005; 257: 531-9. 135
  115. Gotto AM, Whitney E, Stein EA et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000; 101: 477-84. 136
  116. Simes RJ, Marschner IC, Hunt D et al. Relationship between lipid levels and clinical outcomes in the long-term inter- vention with pravastatin in ischemic disease (LIPID) trial. To what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation 2002; 105: 1162-9. 137
  117. Ballantyne CM, Andrews TC, Hsia JA, Kramer JH, Shear C for the ACCESS Study Group. Correlation of non-high-den- sity lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels. Am J Cardiol 2001; 88: 265-9. 138
  118. Vaverkova H, Frohlich J, Jackuliakova D, Novotny D. Comparison of apolipoprotein B and plasma lipids as targets for lipid lowering treatment. Clin Biochem 2005; 38: 509- 13. 139
  119. Faergeman O. Apolipoproteins and guidelines for prevention of cardiovascular disease. J Intern Med 2006; 259: 434-436. 140
  120. Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-96. 142
  121. Pitt B. Low-density lipoprotein cholesterol in patients with stable coronary heart disease -is it time to shift our goals? N Engl J Med 2005; 352: 1483-4 (Editorial). 143
  122. La Rosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-35. 144
  123. Pedersen TR, Faergeman O, Kastelein JJP et al. High-dose atorvastatin vs usual-dose simvastatin for secondary pre- vention after myocardial infarction. The IDEAL Study: a randomized controlled trial. JAMA 2005; 294: 2437-45. 145
  124. Walldius G, Jungner I. Rationale for using apolipoprotein B and apolipoprotein A-I as indicators of cardiac risk and as targets for lipid-lowering therapy. Eur Heart J 2005; 26: 210-2 (Editorial). 146

Cited by

Sorted by citations

Authors
WALLDIUS, G., & JUNGNER, I.
Affiliations
Karolinska Institutet (SE)
Corresponding author
WALLDIUS, G.
Venue
Journal of Internal Medicine
Publisher
Wiley
Published
2006-04-20
Volume
259
Issue
5
Pages
493-519
ISSN
  • 0954-6820 (ISSN-L)
  • 1365-2796
DOI
10.1111/j.1365-2796.2006.01643.x
OpenAlex
W2154998675
Cited by
583
References
14
Citations by year
2026: 27 · 2025: 26 · 2024: 22 · 2023: 21 · 2022: 23 · 2021: 26 · 2020: 29 · 2019: 28 · 2018: 26 · 2017: 25 · 2016: 25 · 2015: 23 · 2014: 27 · 2013: 28 · 2012: 43
FWCI
6.87
Type
journal article
Language
en
Open access
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Journal of Internal Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • AstraZeneca
  • Fondation pour la Médecine de Laboratoire
Topics
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
ApoB/ApoA1 ratio, apolipoprotein B, apolipoprotein A-I, cardiovascular risk factors, atherosclerosis, lipid-lowering therapy, HDL cholesterol, LDL cholesterol, VLDL, intermediate density lipoprotein, myocardial infarction, stroke, cardiovascular risk assessment
MeSH terms
Anticholesteremic Agents, Apolipoproteins B, Cardiovascular Diseases, Cholesterol, Diabetic Angiopathies, Female, Humans, Lipoproteins, Male, Myocardial Infarction, Prospective Studies, Risk Factors, Biomarkers, Apolipoprotein A-I, Stroke, Metabolic Syndrome, Atherosclerosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review